Fig. 4: Outcomes according to the MRD-adjusted ELN2022 risk groups (favorable: ELN2022 favorable or intermediate + MRDneg at HSCT; intermediate: ELN2022 favorable or intermediate + MRDpos at HSCT, adverse: ELN2022 adverse). | Blood Cancer Journal

Fig. 4: Outcomes according to the MRD-adjusted ELN2022 risk groups (favorable: ELN2022 favorable or intermediate + MRDneg at HSCT; intermediate: ELN2022 favorable or intermediate + MRDpos at HSCT, adverse: ELN2022 adverse).

From: Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation

Fig. 4

A Transition plot for patients’ distribution from diagnosis to HSCT, B Cumulative incidence of relapse, C Event-free survival, and D Overall survival in patients transplanted in CR/CRi (n = 327).

Back to article page